Pasadena, CA, United States of America

Melissa G Lechner


Average Co-Inventor Count = 2.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2014-2017

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations by Melissa G. Lechner

Introduction

Melissa G. Lechner is an accomplished inventor based in Pasadena, California. She has made significant contributions to the field of cancer research, particularly in the development of methods for cancer detection and monitoring. With two patents to her name, her work is paving the way for advancements in cancer therapy.

Latest Patents

Her latest patents focus on human myeloid-derived suppressor cell (MDSC) cancer markers. These patents provide methods for determining the presence of cancer, distinguishing between malignant and benign forms, and monitoring cancer progression and relapse. The methods involve evaluating specific markers such as CD33/HLA-DR, CD14/HLA-DR, CD66b/HLA-DR, and CD11b/HLA-DR for the activation of transcription factors like STAT3 and HIF1α. Additionally, her patents describe techniques for inducing human MDSC from healthy donor peripheral blood mononuclear cells by co-culturing them with human solid tumor cell lines.

Career Highlights

Melissa G. Lechner is affiliated with the University of Southern California, where she continues her research and innovation in cancer detection and treatment. Her work is recognized for its potential impact on improving cancer patient outcomes through better diagnostic methods.

Collaborations

One of her notable collaborators is Alan L. Epstein, who works alongside her in advancing their research initiatives.

Conclusion

Melissa G. Lechner's contributions to cancer research through her innovative patents highlight her role as a leading inventor in the field. Her work not only enhances our understanding of cancer but also offers promising avenues for future therapies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…